While some American's were elated with Obama's re-election, Wall Street made it quite clear who it had voted for as markets took a sharp nosedive in a post-election sell off immediately following the President's victory. To many investors, Obama's re-election has placed looming concerns over the Fiscal Cliff to the forefront, asthe automatic round of massive spending cuts and tax hikes now seem inevitable come January 1.And with Democrats maintaining control of the Senate and Republicans dominating the House, many remainunderstandablyconcerned aboutthe split Congress coming up with a viable resolution . For investors, however, Obama's re-election willundoubtedlyhave an impact on everyone's bottom line, with taxes being the main concern. But, of course, on Wall Street, there is always a winning play. Obama's victory has alreadybenefitedone corner of the market healthcare, a sector that has a promising future as the President's win locks in another four years of Obamacare. Currently, there are 30 ETFs available to investors that offer targeted exposure to this potentially lucrative corner of the market.Below, we highlight the already stellar performances of various niche segments of the healthcare ETF space.

Biotech Booming

TickerETFYTD1-Year Return3-Year Return5-Year Return
BBHMarket Vectors Biotech ETF39.56%42.92%76.29%90.34%
FBTNYSE Arca Biotechnology Index Fund30.56%29.25%57.93%68.32%
XBISPDR S&P Biotech ETF25.50%32.21%67.26%39.47%
IBBNasdaq Biotechnology25.04%35.71%69.50%53.68%
PBEDynamic Biotech & Genome11.37%13.98%37.68%13.98%
*Returns as of 11/7/2012
Biotechnology ETFs have certainly held their ground over the last few years, as many companies within the industry continue to be pioneers in the healthcare field. Big names like Amgen Inc. (AMGN), Gliead Sciences Inc (GILD) and one of Forbe's top picks for most innovative companies, Alexion Pharmaceuticals (ALXN), have all enjoyed handsome returns, with many logging in double-digit gains just one day after the election.

Without a doubt, there has been a steady uptrend for these biotech ETFs, as illustrated by the funds' stellar returns. For those looking to make a leveraged play on the sector, ProShares Ultra Nasdaq Biotechnology ETF (BIB) is currently the only option, but be aware that this powerful tool comes with a steep price tag, clocking in at 0.95%. Year-to-date, BIB is up a whopping 46.72% .

Supply Side Winners: Medical Devices

One of the main objectives the President wishes to achieve with Obamacare is the expansion of free preventative services and increased access and affordability. With this consequently comes an increased demand for medicalequipmentand devices as more people enter the healthcare consumer pool. Currently, there are only two ETFs that offer targeted exposure to this niche segment of the healthcare world: iShare's Dow Jones US Medical Devices Index Fund (IHI) and State Street's SPDR S&P Health Care Equiptment ETF (XHE).

Considering these two funds' targeted focus, it is not surprising to see some major overlaps in holdings, with industry leaders likeIntuitiveSurgical (ISRG) and Varian Medical Systems, Inc (VAR) both making appearances in IHI's and XHE's top ten holdings. Year-to-date, XHE has gained 13.56%, while IHI has trailed behind by only a slim margin. For the cost-conscious investors, XHE may be a more appealing option, as it charges 13 basis points lower than IHI .

Pharmaceuticals Power On

TickerETFYTD1-Year Return3-Year Return5-Year Return
PJPDynamic Pharmaceuticals19.26%25.14%97.80%86.73%
IHEDow Jones U.S. Pharmaceutical Index Fund13.14%21.51%67.19%68.91%
PPHMarket Vectors Pharmaceutical ETF10.55%15.67%28.24%0.06%
XPHSPDR S&P Pharmaceuticals ETF9.25%15.17%62.16%73.30%
DRGSGlobal Big Pharma ETN9.23%15.68%n/an/a
*Returns as of 11/7/2012
Following similar logic, pharmaceutical companies are also poised to profit from Obamacare with more individuals seeking preventative care and pharmaceutical treatments. Already, pharma ETFs have rewarded investors with handsome returns over the years, despite theirsomewhatvolatile nature .

The portfolios of many of these ETFs include some of the biggest names in the industry, including Pfizer, Johnson & Johnson, Merk & Co and Abbott Laboratories. For those looking for a global spin on the pharma market, RBS's DRGS is a compelling option, as it offers exposure to pharmaceutical companies from the United States, United Kingdom, Switzerland, Denmark, France,Israel and Canada.

Follow me on Twitter@DPylypczak

Disclosure: No positions at time of writing.

Filed Under: , ,
Tickers in this Article: BBH, BIB, DRGS, FBT, IBB, IHE, IHI, PBE, PJP, PPH, XBI, XHE, XPH

comments powered by Disqus

Trading Center